Pharmafile Logo
Pharmafocus logo
Advanced Search

zealand

Showing 3 posts of 3 posts found.

david_horn_solomon

Silence Therapeutics appoints ex-Akari CEO in top position

July 17, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Akari, CEO, Sanofi, Silence Therapeutics, zealand

Silence Therapeutics has appointed Dr David Horn Solomon as its new Chief Executive Officer (CEO), effective immediately. Solomon will head …

Appointment
sanofi_multaq

FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due

August 22, 2016
Research and Development, Sales and Marketing NDA, Sanofi, appraisal, diabetes, iglarlixi, type 2, type-2, zealand

There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a …

News
sanofi_hq__boetie_hall

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

July 28, 2016
Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …

News
The Gateway to Local Adoption Series

Latest content

NIHR chief scientific adviser visits Huddersfield health innovation campus

September 25, 2026

One in three UK women with migraine say symptoms taken less seriously

September 24, 2026

Report highlights scope to expand day surgery

September 23, 2026

Sygnature formalises drug discovery collaboration with X-Chem

September 22, 2026

Codis appoints Steven Facer as chief commercial officer

September 21, 2026